Integrin adhesion receptors contain an on/off switch that regulates ligand binding affinity and cell adhesion. The switch from "off" to "on" is commonly referred to as integrin activation. The objective of this study was to gain insight into the nature of the on/off switch in platelet integrin ␣ IIb ␤ 3 . Here, we show that a select group of the cysteines, located within the extracellular cysteinerich domain of the ␤ subunit, remain unpaired. These unpaired cysteine residues exhibit the properties of a redox site involved in integrin activation. Alterations to the redox site prevent the inter-conversion between resting and active integrin. Altogether, the study establishes integrin as a direct target for redox modulation, revealing an unappreciated link between cell adhesion and redox biology.
Integrins are transmembrane receptors that mediate cell adhesion and cell migration (1, 2) . The integrin protein family is directly involved in most cell-matrix contacts and cell adhesion events. Many pathologic events, including tumor progression, angiogenesis, and vascular disease, also involve integrins (3) (4) (5) . In most cases cell adhesion is stringently regulated, both spatially and temporally. Spatial regulation is achieved by the expression patterns of the integrins and their various ligands. Temporal regulation of adhesion is conferred by a process called integrin "activation." Activation unshields the integrin ligand binding site, increasing its ligand binding affinity. The activation, and de-activation, of integrins is crucial to events like morphogenesis, tumor cell invasion, and platelet aggregation (6 -8) .
The subject of this study is platelet integrin ␣ IIb ␤ 3 , an excellent paradigm of the integrin protein family. Integrin ␣ IIb ␤ 3 is a particularly relevant model for the study of integrin activation because its function on the platelet requires physiologic activation (9) . Integrin ␣ IIb ␤ 3 is maintained in a resting state on circulating platelets. However, agonists like ADP or thrombin induce activation of the integrin. This activation facilitates the binding of soluble fibrinogen, leading to the formation of a platelet aggregate, or thrombus, that halts the loss of blood. Consequently, activation of ␣ IIb ␤ 3 is key for normal hemostasis. Importantly, though, improper activation of ␣ IIb ␤ 3 can have lethal consequences. Rupture of atherosclerotic plaques can cause activation of ␣ IIb ␤ 3 on platelets and can lead to myocardial infarct (10) .
The precise mechanism by which integrins are activated and de-activated is still not completely understood. A significant body of work has focused on how alterations to integrin cytoplasmic domains control activation. In one well supported model, changes in the conformation of the cytoplasmic tails are thought to release a conformational constraint, or open an "integrin hinge" (11) . The release of this hinge is believed to translate into conformational rearrangements in the extracellular face of the integrin that expose the ligand binding site. The physical association of the integrin cytoplasmic domain with regulatory proteins (12, 13) , and the connection of these domains to intracellular signaling pathways (14) , like those controlled by Ha-Ras and R-Ras (15, 16) , also strongly support the idea that activation can be controlled from the cytoplasm. Activation of integrins by events in the cytoplasm has been termed "inside-out" signaling (for reviews, see Refs. 2, 17, and 18).
The physical size of the integrin extracellular domains far exceeds the size of the cytoplasmic domains, and suggests ample opportunity for regulation at the extracellular face. We recently compared the resting and active forms of ␣ IIb ␤ 3 by high resolution peptide mapping, and identified a difference in their conformation at a disulfide-bonded knot in the extracellular domain of ␤ 3 (19) . This knot comprises the cysteine-rich domain of ␤ 3 and a small segment of the amino terminus. The two are connected by a single long range disulfide bond (20, 21) . No information is available to suggest a mechanism by which the conformational changes to this domain in the ectodomain are enacted during activation. Does the extracellular domain simply respond to conformational modulation initiated within the cytoplasm, or can activation be controlled at this site in the ectodomain independent of factors in the cytoplasm?
Over the last decade, there has been an increased appreciation for the role of redox chemistry in the regulation of biological systems. For example, the vasoactivity of hemoglobin, the function of the NMDA receptor, and the regulation of transcription by OxyR, are all regulated by redox modulation at specific cysteine residues (22) (23) (24) . Could integrin function be modulated in an analogous manner by redox rearrangements within the cysteine-rich domain? Hints of this possibility come from some of the earliest studies on nitric oxide (NO). For example, NO can block platelet adhesive events that are known to involve integrin ␣ IIb ␤ 3 (25) (26) (27) . Nevertheless, little consideration has been given to the possibility that redox agents like NO could regulate cell adhesion by direct action on integrins. There has been no indication that redox modulation within an integrin was even possible, particularly given the belief that all of the cysteine residues within integrins are disulfide-bonded. Here we show that ␣ IIb ␤ 3 contains a small number of free cysteines, and that the redox status of these residues can directly influence activation state. These findings provide the first direct link between redox biology and cell-matrix interac-tions, and have important implications for the mechanisms underlying nitrosative and oxidative stress.
MATERIALS AND METHODS
Purification of ␣ IIb ␤ 3 -The two forms of integrin ␣ IIb ␤ 3 , activation state-1 (AS-1) 1 and AS-2 were purified according to previously published procedures (28 -30) .
Construction of Ligand Affinity Resins-For affinity purification of ␣ IIb ␤ 3 , the peptide KYGRGDS was coupled to CNBr-Sepharose (Amersham Pharmacia Biotech) according to the manufacturer's specifications. To analyze the depth of the integrins' ligand binding pocket, affinity resins were constructed in which the KYGRGDS peptide was coupled to the resin with an extended spacer. This was accomplished using procedures we have reported previously (31) .
Peptide Mapping-Limited digestion of HPDP-modified ␣ IIb ␤ 3 was accomplished with V8 protease (Roche Molecular Biochemicals, sequencing grade) in the presence of 2 mM KYGRGDS. V8 was added to purified ␣ IIb ␤ 3 (1 mg/ml) of 100 g in 100 l of Buffer A (20 mM Tris-HCl, pH 7.4, 150 mM NaCl, 1 mM CaCl 2 , 1 mM MgCl 2 , 0.1% Triton X-100). Protease was added in a ratio of 1:200 (weight to weight) and incubated with integrin at 37°C for 2 h. The reaction was stopped by heating to 65°C. After cooling, the sample was applied to avidinSepharose (Sigma) and incubated at 4°C for 18 h. Then, the beads were washed with buffer A extensively, the bound peptides were eluted with dithiothreitol (DTT), and the peptides were visualized on 10 -20% SDS-PAGE.
Protein and Peptide Mass Fingerprinting-Peptide mass fingerprinting (32, 33) was used to define the composition of the cysteine-containing fragments of ␤ 3 . The procedures for this analysis essentially paralleled those of our prior reports (19, 34) . MALDI-MS spectra were obtained with a Voyager DE-RP MALDI-TOF mass spectrometer (PerSeptive Biosystems) equipped with a nitrogen laser (337 nm, 3-ns pulse). Spectra were collected in reflector mode.
Platelet Isolation and Aggregation-Blood was drawn from healthy human donors into 0.15 volume of acid-citrate/dextrose solution supplemented with 1 M prostaglandin E1 and 1 unit/ml apyrase. Platelets were purified from platelet-rich plasma on an albumin cushion as described (35) . Platelet aggregation experiments were performed with 450 l of purified platelets at 37°C with constant stirring in an optical aggregometer (Chronolog).
Labeling of Cysteines within the Integrin-Modification of free cysteine residues was performed with biotin-BMCC and biotin-HPDP according to the manufacturer's (Pierce) specifications. Briefly, ␣ IIb ␤ 3 was reacted with 0.1 mM amounts of these reagents at ambient temperature for 30 min. Unbound reagent was removed by exhaustive dialysis, and the modified integrin was subjected to further analysis as described under "Results."
To quantity the free cysteines, ␣ IIb ␤ 3 was alkylated with C]iodoacetamide (1:500 molar ratio). The alkylated integrin was quantitatively precipitated with trichloroacetic acid, and the pellet was washed several times with Tyrode's buffer. The final pellet was resuspended in 10% SDS at 50°C, and then subjected to scintillation counting to determine the incorporation of isotope into integrin.
Immunoprecipitation and Western Blotting-Purified platelets were labeled with biotin-BMCC, pelleted by centrifugation, lysed with 1% Triton X-100, and then ␣ IIb ␤ 3 was enriched by an affinity step with concanavalin A-Sepharose. The concanavalin A eluate, containing enriched ␣ IIb ␤ 3 , was resuspended in phosphate-buffered saline containing 1% BSA. This material was subjected to immunoprecipitation with control pre-immune antisera, or antisera T545, which binds to ␤ 3 (36) . The precipitates were washed three times with phosphate-buffered saline, resuspended in SDS-buffer and Laemmli buffer, and resolved on 7.5% SDS-PAGE under non-reducing conditions. Samples were transferred to PVDF membranes, which were probed with HRP-conjugated avidin (Sigma) and then developed according to the manufacturer's instructions.
Activation and De-activation of Integrin-AS-1 was activated in vitro by treatment with 3 mM DTT on ice for 5 min, followed by dialysis to remove excess of DTT. This treatment was found to quantitatively activate all of the treated AS-1 as assessed by the ability of the integrin to bind to RGD-Sepharose. The effect of chemical modification of free cysteines on this activation procedure was measured by first treating AS-1 with 0.1 mM biotin-BMCC, followed by dialysis overnight. The sample was then treated with DTT (3 mM) for 5 min on ice and dialyzed again to remove DTT. The ligand binding function of each sample was assessed with RGD affinity resins comprising either short or long chemical spacers.
AS-2 was converted to a resting conformation by incubation with a mixture of sodium nitroprusside (SNP) and reduced glutathione (GSH). SNP and GSH were added simultaneously. Briefly, 3 mM glutathione and 1 mM SNP were added to 20 g of AS-2 in Buffer A. The reaction was allowed to proceed for 30 min at ambient temperature. Treated samples were then assessed for ligand binding function by measuring their ability to bind to RGD affinity columns in which the RGD is linked to the beads directly (short spacer) or through an extended chemical spacer (see above).
RESULTS
Integrin ␣ IIb ␤ 3 Contains Free Cysteine Residues-Although all integrins contain a large number of cysteines in their extracellular domains, these are all generally believed to be disulfide-bonded. This belief is largely based on disulfide mapping studies carried out on ␤ 3 (21) . Despite the rigor of that study, the bond status of many cysteines within the ␤ 3 subunit could not be ascertained because they are closely spaced within a single domain. Here, we re-examined the status of cysteine residues within integrin using two sulfhydryl modifying agents, biotin-BMCC and biotin-HPDP. Both agents conjugate a biotin to free sulfhydryls. Modification with biotin-HPDP has additional utility because it can be released from the tagged sulfhydryl by reduction.
The resting (AS-1) and active (AS-2) conformers of ␣ IIb ␤ 3 , and a series of control proteins, were modified with biotin-BMCC. Blots of these proteins were probed with HRP-avidin to 1 The abbreviations used are: AS-1, activation state-1; AS-2, activation state-2; PAGE, polyacrylamide gel electrophoresis; PVDF, polyvinylidene difluoride; HRP, horseradish peroxidase; PDI, proteindisulfide isomerase; DTT, dithiothreitol; BSA, bovine serum albumin; SNP, sodium nitroprusside; MS, mass spectroscopy; MALDI, matrixassisted laser desorption/ionization; TOF, time-of-flight; Biotin- assess for incorporation of biotin. Biotin-BMCC failed to label ␣-chymotrypsinogen, which lacks free sulfhydryls (Fig. 1A , lane 1), but it did modify BSA and protein-disulfide isomerase, both of which contain free cysteines (Fig. 1A, lanes 2 and 3) . Biotin-BMCC also strongly labeled both AS-1 and AS-2, primarily on the ␤ 3 subunit (Fig. 1A , lanes 4 and 5). In the absence of modification with biotin-BMCC, no labeling of integrin was detected on blots (lanes 6 and 7). Biotin-HPDP, the reversible modification agent, also modified ␤ 3 integrin. Modification by this probe could be reversed by treatment with reducing agent (Fig. 1B) . These observations are the first to indicate that any integrin contains free cysteine residues. In all cases, the ␣IIb subunit was modified to a substantially lower degree.
AS-1 and AS-2 were consistently labeled with the sulfhydryl modification reagents. However, the possibility existed that only a small fraction of the protein, perhaps a small component that was artifactually denatured during purification, actually contained free cysteines. Therefore, studies were conducted to determine what fraction of the purified integrin contains unpaired cysteine residues (Fig. 2 ). This was accomplished by modifying AS-1 (lanes 1-3) and AS-2 (lanes 4 -6) with biotin-BMCC, and then subjecting the modified integrin to precipitation with an avidin affinity resin (Soft-Link). After labeling, both forms of the integrin could be quantitatively removed from solution by the avidin affinity resin. This finding indicates that virtually all of the purified integrin contains unpaired cysteines.
Free Cysteines within ␣ IIb ␤ 3 on the Platelet Surface-To exclude the possibility that the free cysteines in integrin were an artifact of purification, we used biotin-BMCC to probe ␣ IIb ␤ 3 on the platelet surface. Platelets were isolated from freshly drawn blood on cushions of BSA (35) and then exposed to biotin-BMCC. Following modification, free BMCC was removed by six gentle washes, and the platelets were lysed with detergent. A vast excess of oxidized glutathione and iodoacetamide were included in the lysis buffer to ensure that disulfide bonds were not artifactually reduced as a consequence of lysis. Platelet integrin ␣ IIb ␤ 3 was then immunoprecipitated, and blots of this material were probed with avidin-HRP to visualize biotinylated bands. As illustrated in Fig. 3 (lanes 3 and 5) , platelet ␤ 3 was modified with biotin-BMCC. In experiments that included 12 separate blood donors, platelet ␤ 3 was always labeled with the modification reagent. Modifications to the ␣IIb subunit on the platelet surface were not detected. No modification was detected in the precipitates from pre-immune antisera or in immunoprecipitates from non-modified platelets (data not shown).
Free Sulfhydryls within ␣ IIb ␤ 3 Are Located within the Cysteine-rich Domain of ␤ 3 -To map the location of the free cysteine residues within ␣ IIb ␤ 3 , the integrin was modified with biotin-HPDP and then digested with V8 protease. To limit the extent of digestion, proteolysis was performed in the presence of 2 mM KYGRGDS, which partially stabilizes integrin to proteolysis (19, 28) . Peptide fragments of integrin containing biotin-HPDP were purified on avidin-Sepharose. The column was eluted with DTT, which breaks a bond in HPDP, releasing bound protein. Two protein bands were eluted in this manner (Fig. 4A) . The fragment at 14 kDa corresponds to an avidin monomer that is nonspecifically eluted from the column. The ϳ30-kDa band was excised and further digested with trypsin as described under "Experimental Procedures." The resulting tryptic peptides were then analyzed using MALDI-TOF mass spectrometry. Spectra from two independent experiments are shown (Fig. 4, B and C) . Peaks corresponding to peptide fragments from ␤ 3 are labeled with asterisks (iodoacetamide adducts) and arrows (acrylamide adducts). MALDI-TOF mass spectrometry showed that all of these peptides, eight from the first labeling experiment and six from the second experiment, corresponded to fragments from the cysteine-rich domain of ␤ 3 . The position of each of the detected peptides within ␤ 3 is shown in Fig. 4D (bold and italics) . Based on these analyses, we To assess what fraction of ␣ IIb ␤ 3 contains free cysteine residues, the AS-1 (lanes 1-3) and AS-2 (lanes 4 -6) forms of the protein were modified with biotin-BMCC, and then analyzed for their ability to bind to avidin-Sepharose. Equal fractions of starting material (lanes 1 and  4) , flow-through that failed to bind to avidin-Sepharose (lanes 2 and 5) , and protein retained by the avidin-Sepharose resin (SoftLink) (lanes 3 and 6) were analyzed on SDS-PAGE.
conclude that the ϳ30-kDa fragment comprises a domain that spans residues 400 -650 of ␤ 3 . These observations localize the free cysteine residues of the integrin to the same disulfidebonded knot that exhibits conformational differences in resting versus active integrin (19, 37, 38) .
A Difference in the Number of Free Cysteine Residues in the Resting and Active Conformers of Purified ␣ IIb ␤ 3 -Experiments were conducted to determine if AS-1 and AS-2 exhibit a   FIG. 4 . Localization of the free Cys residues within ␣ IIb ␤ 3 by mass fingerprinting. A, purified ␣ IIb ␤ 3 was modified with biotin-HPDP and digested in solution with V8 protease as described under "Materials and Methods." The fragment of the protein modified with biotin-HPDP was purified by affinity chromatography on avidin-Sepharose, and then eluted with reducing agent. The eluate was analyzed on SDS-PAGE. The eluate of the integrin fragments is shown in lane 2, and the eluate from a control column is shown in lane 3. B and C, the gel-purified fragment of ␤ 3 was reduced and alkylated, and then digested with trypsin. The masses of the resulting peptide fragments were determined by MALDI-TOF mass spectrometry. MALDI profiles of two separate mass fingerprinting experiments are shown (B and C). The mass range extending from 800 to 6000 Da was examined. The peptide peaks corresponding to fragments of ␤ 3 are labeled with asterisks (iodoacetamide adducts) and arrows (acrylamide adducts). D, to illustrate the location of the free cysteines, the amino acid sequence of the cysteine-rich domain of integrin ␤ 3 is shown. All of the predicted cleavage points for trypsin within this domain are noted by lines above the sequence. The monoisotopic mass of the predicted fragments are also shown above each peptide. The masses of peptides detected from mass fingerprinting (B and C) are noted in italics. The peptide extending from residue 423 to 447 is present in the modified ␤ 3 fragment (Fig. 7A) ; therefore, this fragment must also contain the NH 2 terminus of ␤ 3 because the two peptides are connected by the long range disulfide bond between Cys-5 and Cys-435. The position of each of the four cysteine-rich repeats is shown by shading, and the positions of two potential nitrosylation sites are underlined.
difference in the number of unpaired cysteine residues. This was accomplished by alkylation of integrin with [
14 C]iodoacetamide. These studies were performed in denaturing detergent to maximally expose free cysteines. Following alkylation, the integrin was precipitated with trichloroacetic acid and the amount of [ 14 C]iodoacetamide incorporated into the protein was determined by scintillation counting. As shown in Table I , the extent of labeling was remarkably consistent among different batches of integrin, and from experiment to experiment. The measurements show that AS-1 contains between 2 and 3 free cysteines, and that AS-2 contains between 4 and 5 free cysteines. Importantly, in each of six side-by-side comparisons, AS-2 was always found to have two additional free sulfhydryl residues, a value that corresponds to one reduced disulfide bond.
Modification of Free Cysteine Residues of ␣ IIb ␤ 3 Prevents Activation-We and others have previously found that mild reduction of resting ␣ IIb ␤ 3 (AS-1) with DTT can convert it to an active state (19, 28, 39) . This activation could arise from the reduction of a single disulfide bond, or from bond re-shuffling between the free cysteines and existing disulfides. In an attempt to distinguish between these possibilities, we tested the effects of modifying the free cysteines within AS-1 on activation. Activation of the integrin was assessed by its ability to bind to two different RGD affinity resins. The RGD binding site within the resting form of ␣ IIb ␤ 3 is buried, and this conformer can only bind to affinity columns when the RGD peptide is extended from the resin by a long chemical spacer. In contrast, activated ␣ IIb ␤ 3 has a shallow RGD binding site and it can bind to affinity resins where the RGD peptide is linked directly to the resin (19, 28, 40) .
As shown in Fig. 5 , purified AS-1 is unable to bind to KYGRGDS-Sepharose until activated with DTT ( compare  lanes 1 and 3) . Interestingly, however, prior modification of the free cysteines within AS-1 with biotin-BMCC prevented its activation by DTT (lane 4). Such modification with biotin-BMCC blocked the activation of more than 90% of the integrin, as only about 10% of the AS-1 could be stimulated to bind to RGD-Sepharose following activation with DTT. The effects of biotin-BMCC were not due to an inactivation of the RGD binding site on the integrin by biotin-BMCC because modified AS-1 is still able to bind to RGD columns in which the peptide is linked to the resin via a long chemical spacer (lane 5). Furthermore, modification of the free cysteine residues within AS-2 by biotin-BMCC had no effect on its RGD binding function (lane 6). These studies show that chemical modification of the free sulfhydryls in AS-1 can prevent its activation without directly affecting its RGD binding site. These observations strongly indicate that disulfide bond rearrangement is involved in the activation process.
This analysis was extended to determine if modification of the free cysteine residues of ␣ IIb ␤ 3 on the platelet surface could prevent activation. In this case, we used platelet aggregation as a physiologically relevant readout of activation of ␣ IIb ␤ 3 . Platelets were separated from the constituents of plasma, and then the free cysteine residues on the platelet were modified by a brief treatment with biotin-BMCC as described under "Materials and Methods." In the first series of studies, DTT was used as an agonist (Fig. 6A) . As others have reported (39, 41) , DTT induced aggregation of platelets (trace 1), although the rate of aggregation and the size of the aggregates was smaller than when platelets are stimulated by physiologic agonists. Modification of platelets with biotin-BMCC prior to exposure of the platelets to DTT blocked DTT-induced aggregation (trace 2). Similar experiments were conducted with ADP, a physiologic platelet agonist. Modification of platelets with biotin-BMCC also prevented ADP-induced aggregation of platelets (Fig. 6B,  trace 2) . We cannot exclude the possibility that biotin-BMCC also modifies sulfhydryls on other platelet proteins, and that these could be involved in the activation process. Nevertheless, the coherence between the results obtained with purified integrin, and on the platelet surface, strongly indicates a mechanistic link between the free cysteine residues in ␤ 3 and activation.
AS-2 Can Be De-activated by Redox Agents-A series of studies were conducted to explore the converse hypothesis, namely that modification of the free cysteines within AS-2 could convert it to a resting integrin. Because NO and NO donors exhibit potent anti-platelet activity, we reasoned that exposure of AS-2 to nitrosylating conditions may be able to convert it to AS-1. Therefore, we exposed AS-2 to nitrosylating agents and tested its activation state by measuring its ability to bind RGD affinity resins with short and long spacing groups. Two types of modification were tested: direct modification with NO, using nitroprusside as donor, and modification with a mixture of nitroprusside and reduced glutathione (GSH).
As shown in Fig. 7A , exposure of AS-2 to nitroprusside had no effect on the integrins ability to bind to RGD columns lacking a spacer (lane 2). In contrast, inclusion of glutathione during exposure to the NO donor eliminated the ability of the integrin to bind to the RGD column (lane 3). It is important to emphasize that the modification of AS-2 by NO/GSH is not simply denaturation of the integrin because its ligand binding function is retained. It is still able to bind to RGD columns in which the peptide is extended from the resin by a long chemical spacer (lanes 4 -6) . Rather, such modification induces a conformational change that buries the RGD binding site.
In a second series of experiments, we tested the ability of mild reduction to re-activate the de-activated AS-2. AS-2 was de-activated with NO/GSH, dialyzed to remove redox agents, and then treated with mild reduction. As shown in Fig. 7B , native AS-2 and AS-2 treated with glutathione bind the RGD column lacking a spacer (lanes 1-3) . AS-2 de-activated by combined exposure to NO and GSH is unable to bind the column (lane 4). However, this de-activated integrin could be re-activated by mild reduction as indicated by its ability to bind the affinity resin (lane 5). Perhaps not surprisingly, this final treatment with reducing agent also alters, to some extent, the migration of ␣IIb on SDS-PAGE. This subunit also contains disulfide bonds, and exposure to reducing agent during reactivation apparently reduces some of these bonds.
Further experiments were conducted to determine whether exposure of AS-2 to NO/GSH altered the number of free cysteine residues in integrin. Free sulfhydryls were measured by quantifying the incorporation of [ 14 C]iodoacetamide into the protein as described above. AS-2 contained an average of 4.5 free cysteines, but when treated with NO/GSH this value dropped to only 0.5 free cysteines. These observations show that the mixture of NO and GSH modifies the free cysteine residues within AS-2. The de-activated sample that was then re-activated with DTT contained, on average, 5.6 free cysteines, indicating that the modifications induced by NO/GSH can be reversed by reduction.
The fact that a mixture of NO and GSH are required to convert AS-2 to a resting state suggests that the chemical steps leading to conversion may be complex. As discussed by Stamler et al. (42) , when applied together NO and GSH could catalyze a number of reactions within a protein redox site. These could include S-nitrosylation and glutathionylation of cysteine residues on the protein, or disulfide bond formation, or even rearrangement. Although at this juncture we cannot name the chemical species involved in these reactions, the overall findings of this study draws a strong mechanistic link between the status of cysteines within the redox site, and the activation state of the integrin. They also show that physiologic redox modulators that are known to act on platelets in vivo can alter the integrins activation state in vitro.
DISCUSSION
Free Cysteine Residues in the Integrin ␤ 3 Subunit-Fifty-six highly conserved cysteine residues are a hallmark of all integrin ␤ subunits. Based on disulfide mapping experiments, it has generally been assumed that all of these residues are paired in disulfide bonds (21) . No evidence of unpaired cysteines within an integrin has ever been reported. In the present study, we uncovered multiple free cysteine residues within the ␤ 3 subunit. These cysteine residues are present on purified integrin and on the platelet surface.
We have been able to localize the free cysteines to a domain of approximately 200 residues that essentially encompasses the cysteine-rich domain of the ␤ 3 subunit. This region is connected to a smaller cysteine-rich region in the NH 2 terminus of the protein by a long range disulfide bond. We believe that, together, these domains encompass the redox site and act as key modulatory domains in the process of activation.
Evidence for a Redox Switch in Integrin Activation-In conjunction with prior observations in the literature, the findings of the present study can be organized into six major points that support the idea that the free cysteines in ␤ 3 comprise a redox site with a role in integrin activation.
First, AS-1 and AS-2 have a different number of free cysteine residues. AS-1 contains 2-3 free sulfhydryls, whereas AS-2 contains 4 -5, indicating that an overall net reduction of one disulfide bond correlates with a change in activation status. This observation is also consistent with studies showing a dramatic increase in the number of free thiols present on the platelet surface following platelet stimulation (43) .
Second, chemical modification of the free cysteines prevents the activation of AS-1 both in vitro and on the platelet surface. These findings are consistent with a disulfide bond reshuffling mechanism like that shown in Fig. 8 . Thus, tying up free cysteines required in a multistep process of disulfide bond reshuffling prevents activation. These mechanistic observations are likely to explain prior observations showing that DTT activates ␣ IIb ␤ 3 on platelets (39), ␣ L ␤ 2 on monocytes (44, 45) , and even ␣ 5 ␤ 1 on the cell surface (46) . Even though DTTinduced activation is not likely to recapitulate all of the steps involved in physiologic activation, the fact that biotin-BMCC blocks ADP-induced aggregation (Fig. 6) suggests that bond re-shuffling is also an element in physiologic activation. Third, the idea for a redox site involved in activation is strengthened by the observation that AS-2 can be converted to a resting state by the combined action of NO and GSH. The fact that this de-activated AS-2 can then be re-activated by mild reduction solidifies the notion that these agents are acting on a regulatory redox site. These findings are also consistent with the anti-platelet effects of NO/endothelium-derived relaxing factor (25) , and of S-nitroso donors like S-nitrosoalbumin (26) and S-nitroso-N-acetylcysteine (47) .
Fourth, the conformational changes that coincide with activation can be mapped to domains within the disulfide-bonded knot of ␤ 3 . For example, the AP5 antibody that reports on the activation status of both ␤ 3 integrins (38, 48) , binds to the amino-terminal five residues of ␤ 3 (37) . These five residues are brought into proximity with the cysteine-rich repeats of ␤ 3 by the disulfide bond between Cys-5 and Cys-435 (Fig. 4D) . Consequently, chemical changes at the redox site within the cysteine-rich domain are likely to be translated to conformational changes at this epitope in the NH 2 terminus. The N29 antibody that binds in the NH 2 terminus of the ␤1 integrin also reports on the conformational changes that accompany DTT-induced activation of that integrin (46) . Finally, our recent peptide mapping study identified key conformational differences between AS-1 and AS-2 at the disulfide-bonded knot that contains the redox site (19) .
Fifth, mutations within the cysteine-rich domain can cause activation of integrin. For example, Wippler et al. (49) showed that a truncated integrin, lacking the Cys-rich domain of ␤ 3 , is expressed in an activated state. In conjunction with results of the present study, these observations suggest that the cysteinerich domain places an important conformational constraint on the ligand binding site. In addition, a point mutation within the cysteine-rich domain of ␤ 3 causes the integrin to be expressed in a constitutively activated conformation on cells (50) .
Sixth, there is evidence that the activation of ␣ IIb ␤ 3 on the platelet surface can be controlled by platelet protein-disulfide isomerase (PDI). Although in the present study the integrin redox site was manipulated chemically, a physiologic role for PDI in controlling the integrin redox site should not be discounted. PDI can enact the formation of disulfides from free thiols, and also the rearrangement of existing disulfide bonds (51) . PDI has been identified on the platelet surface (52) , and inhibitors of PDI are known to prevent activation of ␣ IIb ␤ 3 on the platelet surface (53) .
Mechanism of Action at the Integrin Redox Site-Protein redox sites can be regulated in many ways, encompassing numerous chemical intermediates, all with varying degrees of stability (42, 54) . Therefore, precise chemical mechanisms must be proposed with caution. Based on the results of this study, we can arrive at a framework that will guide further investigation.
The results of the present study are most consistent with the general mechanism illustrated in Fig. 8 . In this scenario, resting and active integrins differ in the number and position of FIG. 7 . Conversion of AS-2 to AS-1 by altering redox conditions. A, the effect of changes in the redox environment on the function of AS-2 was tested. The ability of integrin to bind affinity resins where the peptide KYGRGDS is linked to beads with either a short (lanes 1-3) or long (lanes 4 -6) chemical spacing groups was used as a readout of activation/inactivation (19, 40) . The ligand binding function of AS-2 ( lanes 1 and 4) , AS-2 treated with NO (lanes 2 and 5), and AS-2 treated simultaneously with NO and glutathione (lanes 3 and 6) was assessed. Integrin bound to the affinity columns was eluted and analyzed on SDS-PAGE. B, similar experiments were performed, along with a test to determine if mild reduction could reverse the effects of NO/GSH on AS-2. In this case, only the binding to the RGD affinity resin with a short chemical spacer was measured because this signifies activation. A model of the proposed rearrangements at the integrin redox site during activation is shown. In the proposed scenario, resting and active integrin differ in the number and position of unpaired cysteine residues (free thiols). The reactive cysteine residues are generally proximal to one another, and are all located within the same domain of integrin. Transition from resting to active integrin proceeds through a series of conformational intermediates, each differing in the position of free cysteines and disulfide bonds. Many of these conformational intermediates are envisioned to be reversible, making it possible for integrin to transit up and down the activation continuum, and enabling modulation of activation state on the cell surface. unpaired cysteines. Thus, activation through this site is likely to involve a series of reactions that proceed through conformational intermediates. These intermediates are likely to represent the continuum of integrin ligand binding affinities proposed by Masumoto and Hemler (55) , and the distinct integrin conformational energy states put forth by Loftus and Liddington (56) . Indeed, one could also envision how all integrin redox intermediates could also fall within the nitrosative/oxidative continuum put forth by Stamler and Hausladen (42) . This chemical continuum of sulfhydryl species distinguishes the modifications to cysteines that constitute biological signals from the alterations that underlie toxicity associated with nitrosative stress.
We cannot exclude more complicated scenarios that involve small molecule redox agents, like NO or glutathione. Indeed, given the level of glutathione in the blood, one might propose that GSH bound to a cysteine in ␤ 3 could maintain the integrin in a resting state. Similarly, integrin activation could be regulated by S-nitrosylation. Many of our findings are consistent with these possibilities. Interestingly, two consensus nitrosylation motifs are present within the cysteine-rich domain of ␤ 3 (Cys-523 and Cys-581). Both cysteine residues are flanked by the acid-base pair thought to be key to nitrosylation in other proteins (57) . In our preliminary attempts to narrow down the position of free cysteines within ␤ 3 , we detected two small tryptic peptides (residues 520 -530 and residues 581-600) that are modified in the native integrin by biotin-HPDP. Each peptide spans one of the consensus nitrosylation sites and contains multiple cysteine residues, underscoring the possibility that NO could act at these sites.
Given the initial framework provided here, future study can be devoted toward an understanding of the chemical detail at the redox site. Considerably more effort will be required to pin down the exact chemical mechanisms that modulate the integrin redox site, especially considering that many of the chemical species involved in such reactions are inherently unstable and difficult to detect. Moreover, there may be more than one chemical pathway in operation at the redox site that has physiologic relevance.
Biological Implications of an Integrin Redox Site-The term "inside-out" signaling is used to describe the activation of integrin via factors in the cytoplasm. Although a wealth of evidence shows that inside-out signaling can control activation state (12, 14, 16, 58) , the findings of this report suggest an important alternative means of regulation. Namely that integrin activation could be controlled directly by a redox site in the extracellular domain, independent of factors in the cytoplasm. The two pathways to activation, inside-out and redox modulation, may serve different purposes. The redox switch could regulate rapid and transient changes in activation state that require no "filtering" through the cytoplasm. Inside-out signaling may then play a larger role in persistent control of activation, a process that may benefit from filters provided by the interconnections among intracellular signaling paths. In sorting out the regulation of cell adhesion, it will be important to understand how interrelated, or independent, these two paths to activation are.
The results presented here also hint at a novel mechanism for the action of endothelium-derived relaxing factor/NO on platelet function. NO donors, including S-nitrosoalbumin, Snitrosohemoglobin and S-nitrosocysteine, all block platelet adhesive events (27, 59) . Furthermore the platelets of mice lacking NO synthase exhibit increased hemostasis (reduced bleeding times) and enhanced platelet recruitment (60) . Moreover, direct inhalation of NO gas inhibits platelet function in humans (61) . These interrelationships between NO and platelet function now have well established clinical significance (62) .
Although the effects of NO on platelets have largely been attributed to the ability of NO to modulate the activity of guanylate cyclase in the cytoplasm, our observations on the integrin redox site suggest that the integrin redox site may be a direct target for NO. Because of the well established links between both NO and ␣ IIb ␤ 3 to coronary syndromes and thrombotic disease, our findings also suggest that the redox site on integrin could be targeted by drugs aimed at preventing thrombosis. This strategy could provide important pharmacologic advantages over the RGD mimics, which have not performed well in recent clinical trials (63) .
